Jonathan Young 10b5-1 Trades: 12,500 AKRO Shares Sold, Options Exercised
Rhea-AI Filing Summary
Jonathan Young, Chief Operating Officer of Akero Therapeutics (AKRO), filed a Form 4 reporting transactions dated 08/12/2025. The filing shows transactions effected pursuant to a Rule 10b5-1 trading plan dated April 29, 2025. The report records an acquisition of 12,500 common shares (and concomitant acquisition of 12,500 stock option rights with an exercise/conversion price of $21.10) and two sales totaling 12,500 shares sold at weighted-average prices of $47.721 and $48.324, respectively.
Following the reported activity the filing lists 197,484 shares beneficially owned directly and derivative holdings of 69,982 option-related instruments. The filing discloses three irrevocable trusts each holding 20,000 shares for the benefit of the reporting person’s children and states the reporting person disclaims beneficial ownership of those trust shares. The option referenced vests in 48 equal monthly installments commencing December 8, 2021.
Positive
- Transactions effected under a Rule 10b5-1 trading plan, reducing questions about opportunistic insider timing
- Full disclosure of trust holdings and disclaimer for three irrevocable trusts (20,000 shares each)
- Vesting schedule for options disclosed (48 monthly installments commencing December 8, 2021), aiding transparency
Negative
- Insider sales of 12,500 shares executed at weighted-average prices of $47.721 and $48.324, which may be perceived as insider liquidity
- Significant remaining direct holdings (reported 197,484 shares) and 69,982 derivative instruments represent ongoing insider exposure that could influence perceptions of insider alignment
Insights
TL;DR: Insider executed matched acquisition and sales under a 10b5-1 plan, leaving direct holdings at ~197k shares; activity appears pre-planned.
The Form 4 shows Jonathan Young used a Rule 10b5-1 plan to effect both an acquisition of 12,500 shares (and related options exercisable at $21.10) and the sale of 12,500 shares across multiple transactions at weighted-average prices near $47.7–$48.3. The matching sizes and the explicit 10b5-1 disclosure reduce inference of opportunistic timing. The report also clarifies indirect holdings via three irrevocable trusts which the reporting person disclaims. For investors, this is informative about insider liquidity actions and remaining direct and derivative exposure.
TL;DR: Disclosure is complete and cites a pre-established trading plan; trusts and disclaimers are properly noted.
The filing includes customary governance disclosures: the trading plan date is provided, sales were consummated at specified weighted-average prices with a commitment to provide transaction-level breakdown if requested, and irrevocable trusts are identified with a disclaimer of beneficial ownership. Vesting terms for the option instruments are disclosed (48 monthly installments starting December 8, 2021). From a compliance perspective the Form 4 appears to meet Section 16 transparency expectations.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) | 12,500 | $0.00 | -- |
| Exercise | Common Stock | 12,500 | $21.10 | $264K |
| Sale | Common Stock | 11,151 | $47.721 | $532K |
| Sale | Common Stock | 1,349 | $48.324 | $65K |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated April 29, 2025, previously adopted by the Reporting Person. These shares are held in irrevocable trusts for the benefit of the Reporting Person's children. The Reporting Person's spouse is trustee of the trusts. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $47.21 to $48.20, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Footnote. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $48.22 to $48.61, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Footnote. This option shall vest and become exercisable in 48 equal monthly installments, commencing on December 8, 2021
